Menu
 

Search abstracts


The efficacy and safety of zepatier treatment experience in hcv genotype 1 patients

  • At: 2018 FIP Congress in Glasgow (Scotland)
  • Type: Poster
  • By: TSAI, Tzu-Cheng (Chang Gung Memorial Hospital, Department of pharmacy)
  • Co-author(s): Tzu-Cheng Tsai
    Shin-Tarng Deng
    Chao-Wei Hsu
  • Abstract:

    Background

    Zepatier (elbasvir and grazoprevir) is a directly acting antivirals (DAA) for treatment of chronic HCV genotype (GT) 1 or 4 infection in adults. It was approved by TFDA since Dec. 2016, then reimbursement for fibrosis 3 or 4 (F3 or 4) by NHI since Aug. 2017. Approximately 53% of HCV infected patients were genotype 1 in Taiwan, DAA was..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 13 May 2019

FIP Congresses